UTHR - CIK 0001082554
The table below shows UNITED THERAPEUTICS Corp's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $1.56B | $1.33B | $978.00M | $802.50M | $598.20M | $755.70M |
| Capital expenditure | $520.50M | $246.50M | $230.40M | $138.80M | $120.80M | $59.30M |
| Investing cash flow | -$551.30M | $417.20M | -$719.60M | -$811.50M | -$486.90M | -$738.50M |
| Dividends paid | - | - | - | - | - | - |
UNITED THERAPEUTICS Corp reported operating cash flow of $1.56B for fiscal year 2025. That is up 17.6% from $1.33B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $643.60M (FY 2016) to $1.56B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $1.00B | $1.00B | $0.00 | $0.00 | - | - |
| Financing cash flow | -$1.15B | -$1.25B | -$11.90M | $75.40M | $44.80M | -$16.90M |